Pfizer 2014 Annual Report Download - page 26

PFIZER ANNUAL REVIEW 2014 www.pzer.com/annual 26
ANNUAL REVIEW 2014
GLOBAL VACCINES, ONCOLOGY
AND CONSUMER HEALTHCARE BUSINESS
Global Vaccines, Oncology and Consumer Healthcare (VOC)
is comprised of three separate, unique businesses that share
certain key elements:
• Each of these businesses is poised for high, organic growth
over time
• Each business requires distinct specializations and operating
models in science, talent and market approach
• Structure provides each business with the dedicated resources
required to further strengthen and position it to be a market leader
on a global basis
Pfizer Vaccines
Pzer Vaccines is uniquely positioned as a future leader in the modern
vaccine era. This is true both for the development of novel vaccines to
prevent infectious diseases of continuing and emerging importance, and
for the development of “therapeutic” vaccines that provide alternative
treatments to manage and control disease. Pzer envisions a shift,
with immunizations moving from a one-time intervention in infancy to a
solution that fosters health and wellness through one’s lifetime. We are
an integrated global vaccine organization with end-to-end capabilities
ranging from basic research, through process and medical development,
to manufacturing and distribution. Our technological and global
manufacturing capabilities are state-of-the-art, and our R&D and medical
vaccine leaders are global industry innovators, all of whom have had
signicant vaccine experience in the industry, in academic institutions,
as well as in non-governmental and governmental organizations.
Collectively, the Pzer Vaccines team has the experience and steadfast
dedication to protect lives with innovative vaccines that ght serious
diseases worldwide.
Pfizer Oncology
The goal of Pzer Oncology is to cure or control cancer by developing
breakthrough medicines that represent great value to patients, their
caregivers and society. On February 3, 2015, the U.S. Food and
Drug Administration (FDA) granted accelerated approval of Ibrance®
(palbociclib), in combination with letrozole, for the treatment of post-
menopausal women with estrogen receptor-positive, human epidermal
growth factor receptor 2-negative (ER+/HER2-) advanced breast cancer
as initial endocrine-based therapy for their metastatic disease. Ibrance,
an oral kinase inhibitor, was reviewed and approved under the FDA’s
Breakthrough Therapy designation and Priority Review programs.
In addition to the great strides that have been made over the past year
making Xalkori,® Inlyta ® and Bosulif ® available to patients around the
globe, Pzer Oncology has a promising late-stage pipeline, including
investigational drugs being studied for the following indications:
Ibrance (palbociclib) for both early and advanced breast cancer and
additional solid tumor indications beyond breast cancer through both
Pzer-sponsored and non-sponsored (investigator-initiated) studies,
inotuzumab ozogamicin for acute lymphoblastic leukemia and dacomitinib
for non-small cell lung cancer. Additionally, Pzer is working to advance
the science in immuno-oncology and actively exploring a variety of
novel approaches, including checkpoint modulating antibodies, CAR-T
therapies, bi-functional monoclonal antibodies and vaccine-based
immunotherapy regimens. Pzer is also exploring the full potential of
combining immunotherapies with its broad oncology portfolio through the
company’s own development efforts, as well as in collaboration with other
partners, working together to improve outcomes for patients with cancer.
Pfizer Consumer Healthcare
Pzer Consumer Healthcare helps consumers around the world
take control of their health and well-being with science-based,
differentiated self-care solutions. We are ranked fth globally among
multinational, branded consumer health care companies, and
second in our largest markets — the U.S., Canada and China. Our
products include over-the-counter (OTC) medicines, supplements and
other treatments that are household names and top sellers in their
categories. We are the only company with two of the top 10 global
OTC brands — Advil ® and Centrum.®
Our Business > How We Are Organized